Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. ESDR070 - Treating Bullous Pemphigoid by Inhibiting FcRn: A Phase 2/3 Trial with Efgartigimod
  1. Home
  2. Publications
  3. ESDR070 - Treating Bullous Pemphigoid by Inhibiting FcRn: A Phase 2/3 Trial with Efgartigimod

ESDR070 - Treating Bullous Pemphigoid by Inhibiting FcRn: A Phase 2/3 Trial with Efgartigimod

Authors:
  • RHRussell Hall
    Russell Hall
  • DCDonna Culton
    Donna Culton
  • ZLZhi Liu
    Zhi Liu
  • HUHideyuki Ujiie
    Hideyuki Ujiie
  • ESEnno Schmidt
    Enno Schmidt
  • DMDedee Murrell
    Dedee Murrell
  • ISIvaylo Stoykov
    Ivaylo Stoykov
  • PVPeter Verheesen
    Peter Verheesen
  • LBLuca Borradori
    Luca Borradori
  • PJPascal Joly
    Pascal Joly

Publisher website
Google Scholar
  • 23 September 2022
    • conference paper
    • Published by Morressier GmbH
    • DOI:10.26226/m.62fa009023ef91001a663bab
Abstract
Efgartigimod (EFG) is an engineered Fc fragment that inhibits the activity of the neonatal Fc receptor (FcRn), thereby reducing the levels of cir | POSTER
Keywords
  • TREATING BULLOUS
  • BULLOUS PEMPHIGOID
  • INHIBITING FCRN
  • EFGARTIGIMOD EFGARTIGIMOD
  • EFG
  • POSTER
  • EFGARTIGIMOD
  • FCRN
  • TREATING
  • PHASE
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.